Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Treatment of ovarian metastases of colorectal and appendiceal carcinoma in the era of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Kuijpers, A M J ; Mehta, A M ; Aalbers, A G J ; van Driel, W J ; Boot, H and Verwaal, V J LU (2014) In European Journal of Surgical Oncology 40(8). p.42-937
Abstract

AIM: To compare outcome of women with ovarian metastasis who underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) to outcome of women without ovarian metastasis who underwent CRS-HIPEC.

METHODS: A prospective CRS-HIPEC database was searched to identify women with surgically treated colorectal carcinoma between 2000 and 2012. Patients with ovarian metastasis were identified and patients with peritoneal carcinomatosis but without ovarian metastasis were included as control cases.

RESULTS: 75 patients with macroscopic ovarian metastasis underwent CRS-HIPEC with curative intent, while 50 female patients without ovarian metastasis were identified who underwent CRS-HIPEC. Patients with ovarian... (More)

AIM: To compare outcome of women with ovarian metastasis who underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) to outcome of women without ovarian metastasis who underwent CRS-HIPEC.

METHODS: A prospective CRS-HIPEC database was searched to identify women with surgically treated colorectal carcinoma between 2000 and 2012. Patients with ovarian metastasis were identified and patients with peritoneal carcinomatosis but without ovarian metastasis were included as control cases.

RESULTS: 75 patients with macroscopic ovarian metastasis underwent CRS-HIPEC with curative intent, while 50 female patients without ovarian metastasis were identified who underwent CRS-HIPEC. Patients with ovarian metastasis more often had a primary appendiceal tumour and had a more extensive intra-abdominal tumour load compared to patients without ovarian metastases. Median follow-up time was 45 months (95% confidence interval (CI): 37-53 months). Overall survival (OS) did not differ significantly between the two groups with a median OS in the ovarian metastasis group of 40 months (95% CI 26-54) compared to 64 months (95% CI 17-111, P = 0.478) in the non-ovarian metastasis group. Recurrence patterns did not differ significantly between groups (p = 0.183).

CONCLUSIONS: Patients with ovarian metastasis of colorectal and appendiceal origin who underwent CRS-HIPEC had similar outcome compared to patients without ovarian metastasis. Given the findings of high coincidence of peritoneal metastases with ovarian metastases and ovarian metastases not being an independent factor for survival after CRS-HIPEC, this procedure should be recommended for patients with peritoneal metastases and ovarian metastases of colorectal and appendiceal carcinoma.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Appendiceal Neoplasms/pathology, Carcinoma/drug therapy, Chemotherapy, Adjuvant, Chemotherapy, Cancer, Regional Perfusion/methods, Colorectal Neoplasms/pathology, Databases, Factual, Disease-Free Survival, Female, Follow-Up Studies, Humans, Hyperthermia, Induced, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Staging, Ovarian Neoplasms/drug therapy, Peritoneal Cavity, Peritoneal Neoplasms/drug therapy, Prospective Studies, Retrospective Studies, Treatment Outcome
in
European Journal of Surgical Oncology
volume
40
issue
8
pages
6 pages
publisher
Elsevier
external identifiers
  • pmid:24630923
  • scopus:84903892800
ISSN
1532-2157
DOI
10.1016/j.ejso.2014.02.238
language
English
LU publication?
no
additional info
Copyright © 2014 Elsevier Ltd. All rights reserved.
id
c744f441-b93d-45b4-b3be-a5cc5320be4b
date added to LUP
2022-04-05 09:50:01
date last changed
2025-07-18 02:01:12
@article{c744f441-b93d-45b4-b3be-a5cc5320be4b,
  abstract     = {{<p>AIM: To compare outcome of women with ovarian metastasis who underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) to outcome of women without ovarian metastasis who underwent CRS-HIPEC.</p><p>METHODS: A prospective CRS-HIPEC database was searched to identify women with surgically treated colorectal carcinoma between 2000 and 2012. Patients with ovarian metastasis were identified and patients with peritoneal carcinomatosis but without ovarian metastasis were included as control cases.</p><p>RESULTS: 75 patients with macroscopic ovarian metastasis underwent CRS-HIPEC with curative intent, while 50 female patients without ovarian metastasis were identified who underwent CRS-HIPEC. Patients with ovarian metastasis more often had a primary appendiceal tumour and had a more extensive intra-abdominal tumour load compared to patients without ovarian metastases. Median follow-up time was 45 months (95% confidence interval (CI): 37-53 months). Overall survival (OS) did not differ significantly between the two groups with a median OS in the ovarian metastasis group of 40 months (95% CI 26-54) compared to 64 months (95% CI 17-111, P = 0.478) in the non-ovarian metastasis group. Recurrence patterns did not differ significantly between groups (p = 0.183).</p><p>CONCLUSIONS: Patients with ovarian metastasis of colorectal and appendiceal origin who underwent CRS-HIPEC had similar outcome compared to patients without ovarian metastasis. Given the findings of high coincidence of peritoneal metastases with ovarian metastases and ovarian metastases not being an independent factor for survival after CRS-HIPEC, this procedure should be recommended for patients with peritoneal metastases and ovarian metastases of colorectal and appendiceal carcinoma.</p>}},
  author       = {{Kuijpers, A M J and Mehta, A M and Aalbers, A G J and van Driel, W J and Boot, H and Verwaal, V J}},
  issn         = {{1532-2157}},
  keywords     = {{Adult; Aged; Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Appendiceal Neoplasms/pathology; Carcinoma/drug therapy; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion/methods; Colorectal Neoplasms/pathology; Databases, Factual; Disease-Free Survival; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Ovarian Neoplasms/drug therapy; Peritoneal Cavity; Peritoneal Neoplasms/drug therapy; Prospective Studies; Retrospective Studies; Treatment Outcome}},
  language     = {{eng}},
  number       = {{8}},
  pages        = {{42--937}},
  publisher    = {{Elsevier}},
  series       = {{European Journal of Surgical Oncology}},
  title        = {{Treatment of ovarian metastases of colorectal and appendiceal carcinoma in the era of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy}},
  url          = {{http://dx.doi.org/10.1016/j.ejso.2014.02.238}},
  doi          = {{10.1016/j.ejso.2014.02.238}},
  volume       = {{40}},
  year         = {{2014}},
}